Enzymes that add and remove histone PTMs have been reported to be of clinical relevance in PCa, including the enhancer of zeste homolog 2 (EZH2), which catalyzes the addition of methyl groups to histone H3 at lysine 27 (H3K27); lysine-specific demethylase 1A (KDM1A, also known as LSD1), which catalyzes the demethylation of mono- and dimethylated lysines, specifically histone H3 at lysines 4 and 9 (H3K4 and H3K9); and lysine-specific demethylase 7B (KDM7B, also known as PHF8), which is selective for mono- and dimethylated states [137,166,167]. The gene discussed is EZH2; the disease is posterior cortical atrophy.